Table 2.
Clinical outcomes
| Clindamycin monotherapy (n = 10) | Clindamycin-benzoyl peroxide gel (n = 10) | |||||
|---|---|---|---|---|---|---|
| baseline | 12 weeks | 16 weeks | baseline | 12 weeks | 16 weeks | |
| IHS4a, median [IQR] | 2 [1.8–2] | 0.5 [0–1.3] | 0 [0–1]* | 2 [2–3] | 1 [0–2.5] | 1 [0–1]** |
| IHS4-55, n (%) | – | 5 (50) | 6 (60) | – | 5 (50) | 6 (60) |
| Pain, median [IQR] | 7 [3.5–7.3] | 2.5 [0.8–5.3]** | 3 [1–4]* | 6.5 [4.8–8] | 3 [0.8–6.5]* | 4.5 [1.8–6.3] |
| Itch, median [IQR] | 6 [3.8–6.3] | 3 [1.5–5.3] | 3.5 [0.8–6] | 5 [2–7] | 3.5 [2.3–5.3] | 4.5 [1.5–6.3] |
| Satisfied, n (%) | – | 8 (80) | 8 (80) | – | 7 (70) | 6 (60) |
| Resistant strainsb, n | 7 | 11 | – | 14 | 13 | – |
Between the two groups, no significant differences were found.
All data was analyzed using the Wilcoxon matched-pair signed-rank test.
IHS4, the International Hidradenitis Suppurativa Severity Score System; IQR, interquartile range.
*Significance at 12 weeks and 16 week compared with baseline: p < 0.05.
**Significance at 12 weeks and 16 week compared with baseline: p < 0.01.
aIHS4 only includes lesions in the treated body site.
bClindamycin-resistant strains.